In patients with PIK3CA-mutant, HR+/HER2– advanced breast cancer, the addition of inavolisib to palbociclib and fulvestrant substantially extended PFS to 17.2 months compared to 7.3 months with placebo. The gene discussed is ERBB2; the disease is breast cancer.